Drug Profile
Research programme: haem oxygenase-1 inhibitors - Ryvu Theapeutics
Alternative Names: SEL303Latest Information Update: 04 Oct 2019
Price :
$50
*
At a glance
- Originator Selvita
- Developer Ryvu Therapeutics
- Class
- Mechanism of Action Decyclizing heme oxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 02 Oct 2019 Selvita is now called Ryvu Therapeutics
- 28 Dec 2018 No recent reports of development identified for research development in Haematological-malignancies in Poland
- 28 Dec 2018 No recent reports of development identified for research development in Solid-tumours in Poland